Crystalvue Medical Corp

Crystalvue Medical Corp maintains a strong liquidity position, with a current ratio of 2.45 and cash and equivalents of TWD 132.0 million, indicating sufficient short-term liquidity to cover obligations. The company's price-to-book ratio of 1.77 and price-to-tangible-book ratio of 1.77 suggest a moderate premium to its equity value, while the low debt-to-equity ratio of 0.01 reflects a conservative capital structure. Profitability metrics show a return on equity (ROE) of 14.29% and return on assets (ROA) of 11.35%, both exceeding the typical thresholds for the medical equipment industry, indicating strong operational efficiency and asset utilization. The company's net income of TWD 146.98 million and operating income of TWD 180.95 million further support its profitability. Crystalvue's revenue is primarily concentrated in its core ophthalmic diagnostic device business, with additional contributions from optical devices, precision instruments, and international trading. The company's geographic exposure is not disclosed in the input data, but its international trading business suggests a degree of diversification. The company's revenue growth trajectory is not explicitly provided, but its operating cash flow of TWD 139.13 million and free cash flow of TWD -77.41 million indicate a mixed cash flow profile, with capital expenditures of TWD -185.19 million suggesting ongoing investment in operations. Risk factors for Crystalvue include low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt-to-equity ratio and strong cash position mitigate credit risk, but the negative free cash flow and high capital expenditures may signal potential liquidity pressures in the future. Recent events and filings do not show any material changes or risks for Crystalvue Medical Corp. The company's financials remain stable, with no significant dilution or liquidity concerns reported in the latest filings.